Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pyrophosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL11779407 | 1.00 | CA1 (0.33) | CA1CA4CA5ACA5BLMNA | |
| Pyrophosphoric Acid SCHEMBL9422113 | 1.00 | CA1 (0.33) | CA1CA4CA5ACA5BLMNA | |
| Pyrophosphoric Acid SCHEMBL1666234 | 1.00 | CA1 (0.33) | CA1CA4CA5ACA5BLMNA | |
| Pyrophosphoric Acid SCHEMBL7106242 | 1.00 | CA1 (0.33) | CA1CA4CA5ACA5BLMNA | |
| Pyrophosphoric Acid SCHEMBL27905891 | 0.96 | CA1 (0.32) | CA1CA4CA5ACA5BLMNA | |
| Pyrophosphoric Acid SCHEMBL5051591 | 0.96 | CA1 (0.32) | CA1CA4CA5ACA5BLMNA | |
| Pyrophosphoric Acid SCHEMBL3409500 | 0.96 | CA1 (0.32) | CA1CA4CA5ACA5BLMNA | |
| Pyrophosphoric Acid SCHEMBL4418857 | 0.96 | LMNA (0.35) | CA1CA4CA5ACA5BLMNA | |
| Pyrophosphoric Acid SCHEMBL18670526 | 0.96 | LMNA (0.35) | CA1CA4CA5ACA5BLMNA | |
| Pyrophosphoric Acid SCHEMBL184653 | 0.96 | LMNA (0.35) | CA1CA4CA5ACA5BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1783 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565326-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2025-06-11 | — | — | EP | claimed |
| WO-2025090498-A1 | ENCAPSULATED MEDIUM CHAIN FATTY ACID SALTS AND ORAL SOLID DOSAGE FORMS DERIVED THEREFROM | ISP INVESTMENTS LLC (US) | 2025-05-01 | — | — | WO | claimed |
| US-12268733-B2 | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase | ALEXION PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| CN-119677725-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| WO-2025042830-A1 | PLATELET-DERIVED GROWTH FACTOR BONE GRAFT PUTTY FORMULATION | BIOMIMETIC THERAPEUTICS, LLC (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2025034540-A1 | IMMUNOSUPPRESSIVE THERAPY TO MITIGATE ANTI-SOLUBLE ALKALINE PHOSPHATASE IMMUNE RESPONSE | ALEXION PHARMACEUTICALS, INC. (US) | 2025-02-13 | — | — | WO | claimed |
| US-20250034114-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | claimed |
| US-20240390558-A1 | PLATE-DERIVED GROWTH FACTOR FORMULATION FOR ENHANCING BONE FUSION | STRYKER CORPORATION | 2024-11-28 | — | — | US | claimed |
| EP-3500289-B1 | ASFOTASE ALFA FOR USE IN TREATING TRACHEOBRONCHOMALACIA | ALEXION PHARMA INC (US) | 2024-10-09 | — | — | EP | claimed |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | claimed |
| US-6287341-B1 | MIXING A REACTIVE AMORPHOUS CALCIUM PHOSPHATE, A SECOND CALCIUM PHOSPHATE THAT HAS A CALCIUM TO PHOSPHATE RATIO OF >OR =1.67, AND A PHYSIOLOGICAL LIQUID IN THE AMOUNT TO PROVIDE A PASTE OR PUTTY; INTRODUCING INTO AN IMPLANT SITE | ETEX CORPORATION | 2001-09-11 | — | — | US | claimed |
| US-6277151-B1 | USING IN VIVO AN AMORPHOUS, HYDRATED CALCIUM PHOSPATE IN AN AQUEOUS SOLUTION OF A PASTE OR PUTTY CONSISTENCY; HAVING A BIOCOMPATIBILITY WITH THE CARTILAGE-FORMING CELL OR PRECURSOR; HARDENING | ETEX CORPORATION | 2001-08-21 | — | — | US | claimed |
| WO-2001020018-A2 | DIAGNOSING AND TREATING ARTHRITIC DISORDERS | MITOKOR (US) | 2001-03-22 | — | — | WO | claimed |
| EP-0941079-A1 | BIOCERAMIC COMPOSITIONS | ETEX CORPORATION (US) | 1999-09-15 | — | — | EP | claimed |
| EP-0936929-A2 | METHOD OF PREPARING A POORLY CRYSTALLINE CALCIUM PHOSPHATE AND METHODS OF ITS USE | ETEX CORPORATION (US) | 1999-08-25 | — | — | EP | claimed |
| WO-1998016209-A9 | BIOCERAMIC COMPOSITIONS | — | 1998-08-13 | — | — | WO | claimed |
| WO-1998016209-A2 | BIOCERAMIC COMPOSITIONS | ETEX CORPORATION (US) | 1998-04-23 | — | — | WO | claimed |
| WO-1998016268-A2 | METHOD OF PREPARING A POORLY CRYSTALLINE CALCIUM PHOSPHATE AND METHODS OF ITS USE | ETEX CORPORATION (US) | 1998-04-23 | — | — | WO | claimed |
| US-4678662-A | IMPROVED TASTE AND FLUORIDE ION STABILITY | MONSANTO COMPANY (US) | 1987-07-07 | — | — | US | claimed |
| EP-0175286-A2 | In vitro cell culture system and method | MCW Research Foundation, Inc. (US) | 1986-03-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | CA1 4161/4885CA4 3858/4885CA5A 1499/4885 |
| US-20250034114-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | CA1 4848/4885CA4 4815/4885CA5A 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.